Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vβ use: A new paradigm for designer allogeneic blood and marrow transplantation

Blood

Volumn 112, Issue 8, 2008, Pages 3517-3525

  Friedman, Thea M ^a,b   Goldgirsh, Kira ^a   Berger, Stephanie A ^a   Zilberberg, Jenny ^a   Filicko O'Hara, Joanne ^c   Flomenberg, Neal ^c   Donato, Michele ^a   Rowley, Scott D ^a   Korngold, Robert ^a,b  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b Touro College and University System   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD3 ANTIBODY; CD4 ANTIGEN DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TACROLIMUS; THYMOCYTE ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MIXED LYMPHOCYTE CULTURE; ORGAN DONOR; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; T LYMPHOCYTE; TIME SERIES ANALYSIS; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BIOSYNTHESIS; BLOOD DISEASE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; COMPLEMENTARITY DETERMINING REGION; CYTOLOGY; INSTRUMENTATION; METABOLISM; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 54049083468     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-145391     Document Type: Article

References (46)

1. Butturini A, Bortin MM, Gale RP. Graft-versusleukemia following bone marrow transplantation. Bone Marrow Transplant. 1987;2:233-242.
2. Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant. 2004; 10:579-590.
3. Hogan WJ, Deeg HJ. Stem cell transplantation: graft-mediated antileukemia effects. Methods Mol Med. 2005;109:421-444.
4. Blazar BR, Taylor PA, Vallera DA.CD4+ and CD8+ T cells each can utilize a perforindependent pathway to mediate lethal graftversus-host disease in major histocompatibility complex-disparate recipients. Transplantation. 1997;64:571-576.
5. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221-234.
6. Zeis M, Uharek L, Hartung G, et al. Graft-vsleukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type GD4+ T cells in mice. Hematol J. 2001;2:136-144.
7. van Lochem E, de Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant. 1992;10:181-183.
8. Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CDS T cells independently of GVHD. Leuk Lymphoma. 1999;33:409-420.
9. Yang YG. The role of interleukin-12 and interferon-gamma in GVH D and GVL. Cytokines Cell Mol Ther. 2000;6:41-46.
10. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood. 2000; 96:4350-4356.
11. Krijanovski Ol, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versusleukemia effects from graft-versus-host disease. Blood. 1999;94:825-831.
12. Munshi NC, Govindarajan R, Drake R, et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood. 1997;89:1334-1340.
13. Ciceri F, Bonini C, Gallo-Stampino C, Bordignon C. Modulation of GvHD by suicide-gene transduced donor T Iymphocytes: clinical applications in mismatched transplantation. Cytotherapy. 2005;7:144-149.
14. Jones SC, Murphy GF, Korngold R. Posthematopoietic cell transplantation control of graftversus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2000;9: 243-256.
15. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graftversus-tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150.
16. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant. 1993;11:329-336.
17. Kolb HJ, Gunther W, Schumm M, et al. Adoptive immunotherapy in canine chimeras. Transplantation. 1997;63:430-436.
18. Fehse B, Frerk O, Goldmann M, et al. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol. 2000; 109:644-651.
19. Garderet L, Snell V, Przepiorka D, et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation. 1999;67:124-130.
20. van DijkAM, Kessler FL, Stadhouders-Keet SA, et al. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol. 1999;107:169-175.
21. Godfrey WR, Krampf MR, Taylor PA, et al. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood. 2004;103:1158-1165.
22. Rencher SD, Houston JA, Lockey TD, Hurwitz JL. Eliminating graft-versus-host potential from T cell immunotherapeutic populations. Bone Marrow Transplant. 1996;18:415-420.
23. Martins SL, St John LS, Champlin RE, et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood. 2004;104:3429-3436.
24. Solomon SR, Tran T, Carter CS, et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy. 2002;4:395-406.
25. Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T cells by a specific antiinterleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999;93:3550-3557.
26. Davies JK, Koh MB, Lowdell MW. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant. 2004;10:259-268.
27. Guimond M, Balassy A, Barrette M, et al. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood. 2002;100:375-382.
28. Chen BJ, Liu C, Cui X, et al. Prevention of graftversus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. Transplantation. 2000;70:1442-1447.
29. Solomon SR, Mielke S. Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graftversus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005;106:1123-1129.
30. Mundhada S, Shaw J, Mori S, et al. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses. Leuk Lymphoma. 2005;46:571-580.
31. Cui Y, Kelleher E, Straley E. et al. Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nat Med. 2003;9:952-958.
32. Moyer JS, Maine G, Mule JJ. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol Blood Marrow Transplant. 2006; 12:1010-1019.
33. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J. 2004;10:1-7.
34. Friedman TM, Gilbert M, Briggs C, Korngold R. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease. J Immunol. 1998;161: 41-48.
35. Friedman TM, Station D, Jones SC, et al. Vbeta spectratype analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate. Biol Blood Marrow Transplant. 2001;7:2-13.
36. Patterson AE, Korngold R. Infusion of select leukemia-reactive TCR Vbeta+ T cells provides graft-versus-leukemia responses with minimization of graft-versus-host disease following murine hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:187-196.
37. Satoh T, Aramini JM, Li S, et. al. Bioactive peptide design based on protein surface epitopes. Acyclic heptapeptide mimics CD4 domain 1 CC' loop and inhibits CD4 biological function. J Biol Chem. 1997;272:12175-12180.
38. Friedman TM, Varadi G, Hopely DD, et al. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. Biol Blood Marrow Transplant. 2001;7:656-664.
39. Friedman TM, Reddy AP, Wassell R, et al. Identification of a human CD4-CDR3-like surface involved in CD4+ T cell function. J Biol Chem. 1996;271:22635-22640.
40. Friedman TM, Jones SC, Statton D, et al. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versushost disease directed to minor histocompatibility antigens. Biol Blood Marrow Transplant. 2004;10: 224-235.
41. DiRienzo CG, Murphy GF, Jones SC, et al. T-cell receptor Valpha spectratype analysis of a CD4-mediated T-cell response against minor histocompatibility antigens involved in severe graftversus-host disease. Biol Blood Marrow Transplant. 2006;12:818-827.
42. Jones SC, Friedman TM, Murphy GF, Korngold R. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graftversus-host disease directed to multiple minor histocompatibility antigens. Biol Blood Marrow Transplant. 2004;10:91-105.
43. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: and update of the Seatttle experience. Bone Marrow Transplant. 2000;26:397-404.
44. Lickliter JD, McGlave PB, DeForTE, et al. Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation. Bone Marrow Transplant. 2000;26: 723-728.
45. Dominietto A, Lamparelli T, Raiola AM, etal. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood. 2002;100:3930-3934.
46. Vicente D, Lamparelli T, Gualandi F, et al. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant. 2007;40:349-354.